CBLL
CeriBell, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$24.68
+0.46%Aug 25, 2026, 23:50 UTC
Ceribell President and CEO Chao Xingjuan sold 6,068 shares of Ceribell common stock at $24.02 per share, totaling $145,753, on August 21, 2026, to cover tax withholding obligations related to RSU vesting.
Source:Aug 11, 2026, 09:28 UTC
CeriBell, Inc. held its Q2 2026 earnings call on August 11, 2026, to discuss financial results.
Aug 10, 2026, 22:56 UTC
CeriBell, Inc. reported a second-quarter loss of $0.51 per share, missing the Zacks Consensus Estimate of a $0.45 loss and widening from a $0.38 loss a year earlier.
Source:Aug 10, 2026, 22:04 UTC
CeriBell plans to commercially launch its delirium-monitoring solution later this year.
Source:Aug 10, 2026, 11:00 UTC
Ceribell received FDA 510(k) clearance for two new AI algorithm enhancements, Epileptiform Abnormality Detection and Artifact Reduction, integrated into its cloud-based Neurology Portal for critical-care EEG review.
Source:Aug 3, 2026, 11:00 UTC
Ceribell received CMS New Technology Add-On Payment (NTAP) for its point-of-care delirium monitor system, which may broaden access to its dual seizure and delirium monitoring platform.
Source:Jul 30, 2026, 00:00 UTC
Ceribell, Inc. appointed William W. Burke as a Class II director, Joseph M. Taylor as a Class III director, Sharon L. O'Keefe as a Class I director, and Thomas A. West as a Class I director, effective July 28, 2026.